dc.contributor.author | López Santillán, María | |
dc.contributor.author | López López, Elixabet | |
dc.contributor.author | Álvarez González, Paula | |
dc.contributor.author | Martinez López, Garazi | |
dc.contributor.author | Arzuaga Mendez, Javier | |
dc.contributor.author | Ruiz Díaz, Irune | |
dc.contributor.author | Guerra Merino, Isabel | |
dc.contributor.author | Gutiérrez Camino, Ángela | |
dc.contributor.author | Martín Guerrero, Idoia | |
dc.date.accessioned | 2021-10-04T11:24:13Z | |
dc.date.available | 2021-10-04T11:24:13Z | |
dc.date.issued | 2021-09 | |
dc.identifier.citation | Critical Reviews in Oncology Hematology 165 : (2021) // Article ID 103430 | es_ES |
dc.identifier.issn | 1040-8428 | |
dc.identifier.issn | 1879-0461 | |
dc.identifier.uri | http://hdl.handle.net/10810/53215 | |
dc.description.abstract | Diffuse large B-cell lymphoma (DLBCL), the most common type of Non-Hodgkin lymphoma (NHL), is a highly heterogeneous and aggressive disease. Regardless of this heterogeneity, all patients receive the same first-line therapy, which fails in 30-40 % of patients, who are either refractory or relapse after remission. With the aim of stratifying patients to improve treatment outcome, different clinical and genetic biomarkers have been studied. The present systematic review aimed to identify somatic mutations that could serve as prognosis biomarkers or as therapeutic target mutations in DLBCL. Regarding their role as prognostic markers, mutations in CD58 and TP53 seem the most promising predictors of poor outcome although the combination of different alterations and other prognostic factors could be a more powerful strategy. On the other hand, different approaches regarding targeted therapy have been proposed. Therefore, mutational analysis could help guide treatment choice in DLBCL yet further studies and clinical trials are needed. | es_ES |
dc.description.sponsorship | This study was funded by the Basque Government (IT989-16) and EiTB maratoia/Bioef (BIO15/CA/022/BC) . AGC was supported by a post-doctoral grant from the Basque Government. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.subject | diffuse large B-cell lymphoma | es_ES |
dc.subject | somatic mutation | es_ES |
dc.subject | outcome | es_ES |
dc.subject | hherapeutic target | es_ES |
dc.subject | P53 gene-mutationspoor survival | es_ES |
dc.subject | tumor-suppressor | es_ES |
dc.subject | rituximab-chop | es_ES |
dc.subject | TP53 | es_ES |
dc.subject | predict | es_ES |
dc.subject | EZH2 | es_ES |
dc.subject | classification | es_ES |
dc.subject | methylation | es_ES |
dc.subject | disruption | es_ES |
dc.title | Prognostic and therapeutic value of somatic mutations in diffuse large B-cell lymphoma: A systematic review | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.holder | This is an open access article distributed under the terms of the Creative Commons CC-BY license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. | es_ES |
dc.rights.holder | Atribución 3.0 España | * |
dc.relation.publisherversion | https://www.sciencedirect.com/science/article/pii/S1040842821002183?via%3Dihub | es_ES |
dc.identifier.doi | 10.1016/j.critrevonc.2021.103430 | |
dc.departamentoes | Genética, antropología física y fisiología animal | es_ES |
dc.departamentoeu | Genetika,antropologia fisikoa eta animalien fisiologia | es_ES |